New hope for Hard-to-Treat GI cancers? phase II trial launches
NCT ID NCT06008054
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study is testing whether a new drug called SI-B003, alone or combined with BL-B01D1 or a PD-1 antibody, can shrink tumors in people with advanced esophageal, gastric, or colorectal cancer. About 376 participants will receive the treatments intravenously every three weeks. The goal is to see how well the drugs work and if they are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SI-B003 (a drug), BL-B01D1 (also called iza-bren or izalontamab brengitecan), and a PD-1 monoclonal antibody
What this could lead to
If successful, this could point toward new treatment options for people with advanced gastrointestinal cancers that are hard to treat.
What could go wrong
This is an early-phase trial with no guarantee of success. The treatments may cause side effects or not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact